Publications and reports
Below is a list of publications that use data held by the Cancer Institute NSW.
This includes:
- NSW Cancer Registry
- NSW Clinical Cancer Registry (2008–2012)
- BreastScreen NSW
- NSW Pap Test Register
- Cancer Institute Tobacco Tracking Survey
Published date 13 October 2020
Geriatric oncology patients are less likely to receive radiotherapy than their younger counterparts.
Published date 12 October 2020
Previously opioid-treated people had more intense opioid use patterns after diagnosis than opioid-naïve people.
Published date 11 October 2020
Alcohol consumption confers a significant risk of cancer, and drinking pattern may be independently related to breast cancer risk.
Published date 07 October 2020
Source:
BMJ. 2020 Oct 7;371:m3503
Patients receiving initial active treatment for localised prostate cancer had generally worse long term self-reported quality of life than men without a diagnosis of prostate cancer.
Published date 14 September 2020
The public subsidy of the oxycodone/naloxone controlled-release formulation expanded the overall oxycodone controlled-release market for DVA healthcare card holders with cancer. There is a need for updated guidelines around risk management for opioid treatment in patients with cancer.
Published date 14 September 2020
The risk of developing a subsequent primary melanoma varies considerably between individuals & is particularly high for those with two or more previous melanomas.
Published date 31 August 2020
Lung cancer related healthcare costs appeared stable over the period 2006-2013.
Published date 26 August 2020
Treatment patterns for AYA patients were similar to those for pediatric and for adult patients. Poor outcomes for high-grade gliomas and primitive neuroectodermal tumors highlight the need for clinical trials and novel treatment approaches.
Published date 11 August 2020
Elevated serum CA19-9 concentration is a valid marker for CT-occult unresectable features. Clinical trials which evaluate the value of CA19-9 in the staging algorithm for pancreatic cancer are needed before it is routinely used in clinical practice.
Published date 03 August 2020
Hydrochlorothiazide treatment was associated with an increased risk of both lip cancer and cutaneous melanoma, suggesting that hydrochlorothiazide's photosensitising properties may promote carcinogenesis in sun-exposed tissues.
